“This year, Nabota’s global market will expand in earnest”
[서울파이낸스 김현경 기자] Daewoong Pharmaceutical reappointed the representatives of Jeon Seung-ho and Yoon Jae-chun respectively. On the 26th, Daewoong Pharmaceutical announced that it had reappointed the existing CEO at the regular shareholders’ meeting held at the headquarters in Samseong-dong, Gangnam-gu, Seoul, and newly appointed Lee Chang-jae, vice president of Daewoong Pharmaceutical, as the executive director. As the outside director, Hong-cheol Kim was reappointed as the current outside director, and Young-jin Kim, president of Guro Wooridul Hospital, was newly appointed.
Seung-ho Jeon, CEO of Daewoong Pharmaceutical said, “Daewoong Pharmaceutical is continuously investing in R&D and expanding open innovation and overseas partnerships. This year, we are expanding the global market of Nabota in earnest, and “We will increase the company’s value by visualizing the performance of Jan and Inabogliflozin.”
Daewoong Pharmaceutical’s parent company, Daewoong, newly appointed Park Seong-soo, head of Daewoong Pharmaceutical’s Nabota Business Division as internal director. Park joined Daewoong Pharmaceutical in 1999, worked as the head of the development, global and marketing departments, and the US subsidiary, and is currently the head of the Nabota business division, overseeing Daewoong Pharmaceutical’s botulinum toxin business.
Jae-chun Yoon, CEO of Daewoong, said, “Daewoong is creating management performance based on the solid performance of its subsidiaries such as Daewoong Pharmaceutical and Daewoong Bio despite difficult conditions. This year, Daewoong will focus on the original role of the holding company and I will support their growth,” he said.
Copyright © Seoul Finance Unauthorized reproduction and redistribution are prohibited.